Pure Global AI
NCT06066424Recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

M.D. Anderson Cancer CenterPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
Rimiducid
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Oct 24, 2023
End date
Apr 30, 2040
Enrollment
54 participants
Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To find the recommended dose of TROP2- CAR-NK cells that can be given to patients with
 advanced forms of solid tumors.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06066424
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06066424 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.